Join
Live feed
·
PRReleasevia Quantisnow
Xenon Pharmaceuticals Inc. logo

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

ByQuantisnow·Wall Street's wire, on your screen.
XENE· Xenon Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XENE (Xenon Pharmaceuticals Inc.) and more on Quantisnow.